Clinical trials: Fibrosing Interstitial Lung Disease
Interstitial Lung Disease
Patient-Reported Outcome Study of Project ECHO for ILD
The study will assess whether patients of providers participating in Project ECHO for ILD experience reduced stress, including financial stress, based on their ability to receive timely and local care and services, The study will…
- Trial name
- NCT05450276
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Pulmonary Care and Research Collaborative Limited
Lung Diseases, Interstitial Lung Disease
Effects of Exercise Training on Respiratory Performance in Patients With Fibrosing Interstitial Lung Diseases
The current study recruited patients with fibrosing interstitial lung diseases (f-ILD) whatever was the underlying pathology. The investigators aimed to compare the effects of aerobic exercises for lower limbs (LL) versus upper…
- Conditions
- Lung Diseases, Interstitial Lung Disease, Fibrosis Lung
- Trial name
- ET-fILD (NCT05227443)
- Testing
- Exercise aerobic training, Upper, lower and breathing (ULB) exercise
- Where
- Egypt
- Volunteers
- 31 people
- Sponsor
- Alexandria University
Idiopathic Pulmonary Fibrosis
Azathioprine and Prednisone in the Treatment of Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis (IPF) is a diffuse lung disease, associated with the histological appearance of usual interstitial pneumonia (UIP), with an inexorably deteriorating clinical course.
- Trial name
- NCT00518310
- Testing
- AZAPRED
- Where
- Chile
- Volunteers
- 100 people
- Sponsor
- Thorax National Institute
Fibrosing Interstitial Lung Disease, Telerehabilitation
Telerehabilitation in Patients With Fibrosing Interstitial Lung Diseases
The aim of the study is to determine the effectiveness of different exercise programs applied to 3 groups randomly formed in patients with fibrosing interstitial lung disease (FILD).
- Trial name
- NCT05166057
- Testing
- Synchronized online telerehabilitation exercise program, Videobased telerehabilitation exercise program, Hospital based outpatient exercise program
- Where
- Turkey (Türkiye)
- Volunteers
- 63 people
- Sponsor
- Saglik Bilimleri Universitesi
Lung Diseases, Interstitial
An Expanded Access Program in Belgium to Provide Nintedanib to People With Lung Diseases Called Non-IPF ILDs Who Have no Alternative Treatment Options
This Expanded Access Program in Belgium is open to people with different lung diseases. This program provides a medicine called nintedanib to people who have no alternative treatment options.
- Trial name
- NCT04739150
- Testing
- nintedanib
- Where
- 14 sites in Belgium
- Sponsor
- Boehringer Ingelheim
Lung Diseases, Interstitial
A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)
This study is open to adults with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs). People who have a form of PF-ILD other than Idiopathic Pulmonary Fibrosis (IPF) can join the study.
- Trial name
- NCT05321082
- Testing
- BI 1015550
- Where
- 400 sites in United States, Argentina and 43 more
- Volunteers
- 1,178 people
- Sponsor
- Boehringer Ingelheim
Alveolitis, Fibrosing, Fibrosis, Pulmonary
Sildenafil Study to Treat Idiopathic Pulmonary Fibrosis
Medicines that decrease blood pressure in the lungs may help idiopathic pulmonary fibrosis (IPF) patients function better. This study will test whether sildenafil improves the ability to exercise in patients with pulmonary…
- Conditions
- Alveolitis, Fibrosing, Fibrosis, Pulmonary, Hypertension, Pulmonary
- Trial name
- NCT00359736
- Testing
- sildenafil
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- VA Office of Research and Development
Idiopathic Pulmonary Fibrosis
Study of ORJ-001 for the Treatment of IPF
ORJ-001 is a new class of drugs intended for the treatment of patients with idiopathic pulmonary fibrosis (IPF). This is a Phase 2 study in two parts; the objective of Part A will determine if ORJ-001 is well-tolerated by…
- Trial name
- NCT07869147
- Testing
- ORJ-001
- Where
- 2 sites in United States
- Volunteers
- 95 people
- Sponsor
- Oorja Bio, Inc.
Lung Diseases, Interstitial
Efficacy and Safety of Olokizumab in Patients With Progressive Fibrosing Interstitial Lung Diseases
The purpose of this study is to evaluate efficacy and safety of olokizumab (OKZ) compared to placebo in patients progressive fibrosing Interstitial lung diseases (ILD).
- Trial name
- NCT06440746
- Testing
- Subcutaneous (SC) injections of OKZ 64 milligrams (mg) every 4 weeks (q4w), one injection of 0.4 millilitre (mL)
- Where
- 33 sites in Russia
- Volunteers
- 138 people
- Sponsor
- R-Pharm International, LLC
Fibrosing Interstitial Lung Disease
Prospective Cohort of Patients With Fibrosing Interstitial Lung Disease Admitted for Acute Respiratory Failure
This prospective, multicenter study focuses on patients with fibrosing interstitial lung diseases (ILD) admitted to intensive care units (ICUs) for acute respiratory failure (ARF).
- Trial name
- PIDREA (NCT06855004)
- Where
- France
- Volunteers
- 250 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Progressive Fibrosing Interstitial Lung Disease
Hyperpolarized 129-Xenon MRI in Fibrosing Interstitial Lung Disease
This project aims to investigate the potential of non-invasive imaging to identify and monitor the earliest signs and physiological effects of pulmonary fibrosis and resulting cardiac dysfunction in patients with fibrosing…
- Trial name
- NCT05914506
- Testing
- Hyperpolarized xenon-129 MRI
- Where
- Denmark
- Volunteers
- 30 people
- Sponsor
- University of Aarhus
Progressive Fibrosing Interstitial Lung Disease
Efficacy & Safety of Nintedanib in Patients With Progressive Fibrosing Coal Mine Dust-Induced Interstitial Lung Disease
Assess efficacy (as measured by annual rate of decline in FVC) and safety. The hypothesis is that nintedanib will be safe and effective therapy for patients with progressive fibrosing CMD-ILD over a period of 52 weeks.
- Trial name
- NCT05067517
- Testing
- Nintedanib
- Sponsor
- West Virginia University
Lung Diseases, Interstitial
Correlation Between Changes in Lung Function and Changes in Cough and Dyspnoea in Nintedanib-treated Connective Tissue Disease Interstitial Lung Disease (CTD-ILD) Patients
The aim of this study is to identify correlations between change from the baseline at Month 24 in Forced Vital Capacity (FVC) (% predicted and mL) and change from the baseline at Month 24 in cough or dyspnoea scores [points] as…
- Trial name
- NCT05503030
- Testing
- Nintedanib
- Where
- 20 sites in Greece
- Volunteers
- 88 people
- Sponsor
- Boehringer Ingelheim
Lung Diseases, Interstitial, Lung Disease With Systemic Sclerosis
Non-interventional Study Describing Epidemiology, Prognosis and Patient Healthcare Costs in France, 2010-2017
Interstitial lung diseases (ILDs) are a heterogeneous group of disorders, which encompass a wide range of conditions. In some patients with fibrosing ILDs, a progressive phenotype similar to that observed in idiopathic pulmonary…
- Trial name
- PROGRESS (NCT03858842)
- Testing
- epidemiology, healthcare costs in non-IPF PF-ILD and SSc-ILD
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Hospices Civils de Lyon
Lung Diseases, Interstitial
Study of Progression to Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Incidence/Management and Treatment
The primary objective for this trial is to investigate the incidence probability of progression to Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) in patients with fibrosing ILD other than Idiopathic Pulmonary Fibrosis…
- Trial name
- NCT05875532
- Where
- United States
- Volunteers
- 34,960 people
- Sponsor
- Boehringer Ingelheim
Fibrosing Interstitial Lung Diseases, Thoracic Ultrasound
Ultrasound Applicability in the Assessment of Patients With Fibrosing Interstitial Lung Disease
In this study the investigators want to examine the different ultrasound techniques to assess the patients with lung fibrosis. The investigators want to followup these patients in 1 year to see the changes in lungs, pleura…
- Trial name
- LORD (NCT06844331)
- Testing
- Thoracic ultrasound
- Where
- Denmark
- Volunteers
- 117 people
- Sponsor
- Odense University Hospital
Fibrosing Interstitial Lung Diseases, Idiopathic Pulmonary Fibrosis
Yoga in Patients With Fibrosing Interstitial Lung Diseases
Fibrosing interstitial lung diseases are characterized by loss of lung function, which leads to a decrease in quality of life and physical capacity.
- Trial name
- NCT03979703
- Testing
- 12 week yoga class
- Where
- Germany
- Volunteers
- 17 people
- Sponsor
- Heidelberg University
Lung Diseases, Interstitial
Post-marketing Surveillance of Ofev Capsules in Chronic Fibrosing Interstitial Lung Diseases With a Progressive Phenotype in Japan
The primary objective is to evaluate the incidence of adverse drug reactions (focus on hepatic function disorders) of Ofev Capsules under the real world setting in patients with Chronic fibrosing Interstitial Lung Diseases with a…
- Trial name
- NCT04559581
- Testing
- Nintedanib
- Where
- Japan
- Volunteers
- 425 people
- Sponsor
- Boehringer Ingelheim
Emphysema, Alveolitis, Fibrosing
Assessment of Heart and Heart-Lung Transplant Patient Outcomes Following Pulmonary Rehabilitation
At present, a specific community based rehabilitation programme for lung or heart-lung transplant recipients does not exist. 160 hospitals throughout the United Kingdom (UK) offer pulmonary rehabilitation programmes.
- Conditions
- Emphysema, Alveolitis, Fibrosing, Cystic Fibrosis, Bronchiectasis
- Trial name
- NCT00129350
- Testing
- Pulmonary rehabilitation programme
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- Royal Brompton & Harefield NHS Foundation Trust
Lung Diseases, Interstitial
A Study to Test How Well a Medicine Called Nintedanib Helps People in China With Progressive Lung Fibrosis
This study in China is open to people with progressive lung fibrosis (chronic fibrosing ILDs with progressive phenotype) who are at least 18 years old.
- Trial name
- NCT05065190
- Testing
- Nintedanib
- Where
- 16 sites in China
- Volunteers
- 81 people
- Sponsor
- Boehringer Ingelheim